Previsión

El precio objetivo medio de los analistas es de +12,01€ (+69,87%). La mediana es de +11,16€ (+57,85%).

Comprar	6
Mantener	0
Vender	0

Noticias Ir al feed de noticias

Achieve Life Sciences appoints Jeff Farrow and Dr. Reid Waldman to the board

Achieve Life Sciences has appointed Jeff Farrow and Dr. Reid Waldman to the board effective Thursday. Farrow will chair the audit committee and serve on the nominating and corporate governance committee; Waldman will chair the compensation committee and serve on the trade committee. Both will receive the standard external director compensation (pro rata annual base cash compensation of $40,000, plus additional cash payments for committee service) and will each be granted an option on 47,250 common shares that vests monthly over three years; the appointments were reported in an 8‑K filed with the SEC. The company recently saw a strong share price rise (last week +16%, YTD +36%), reported Q1 EPS of -$0.19 (better than expected), and presented positive long-term safety data for Cytisiniclin from the ORCA-OL study. » Más en de.investing.com
Achieve Life Sciences beats EPS expectations thanks to cost cuts and reports $180 million financing inflow

Achieve Life Sciences reported Q1 2026 EPS of -$0.19, a positive surprise versus the consensus estimate of -$0.43. The company secured $180 million in fresh capital and highlighted promising clinical data for Cytisiniclin. Management plans to resubmit the NDA in Q4 2026 with a target launch in the first half of 2027, but notes risks from production changes and regulatory delays. » Más en de.investing.com
Achieve Life Sciences strengthens leadership team ahead of Cytisiniclin market launch

Achieve Life Sciences appoints three former Verona executives to leadership roles (Christopher Martin to the board, Mark Zappia as senior VP commercial and Jim Willis as VP sales) to prepare for the potential market launch of Cytisiniclin for smoking cessation. Earlier, Andrew D. Goldberg was named CEO and the company secured up to $354 million in financing, including a $180 million upfront payment and up to $174 million in milestone payments contingent on FDA approval. The FDA set the PDUFA date for the new drug application as June 20, 2026; Achieve has submitted phase 3 data and additional studies. The stock is trading near its 52-week high and has returned 125% year-to-date; analysts see price targets between $10 and $20 but warn of possible overvaluation. » Más en de.investing.com

Dividendos históricos Dividendos

Todas las métricas de dividendos Todas las métricas

En 2022, Achieve Life Sciences ya ha pagado 1,18€ en dividendos. El último pago fue en marzo 2022.

Datos financieros de la empresa

En el último trimestre, Achieve Life Sciences tuvo unos ingresos de 0,00€ y un beneficio neto de −65,51 Mio€

(EUR)	jun 2026	YoY
Ingresos	0,00	-
Beneficio bruto	0,00	-
Beneficio neto	−65,51 Mio	507,16%
EBITDA	−65,22 Mio	516,36%

Datos fundamentales

Métrica	Valor
Capitalización bursátil	+720,59 Mio€
Número de acciones	102,66 Mio
Máximo/mínimo de 52 semanas	+7,39€ - +2,25€
Dividendos	No
Beta	2,23
Ratio P/E	−5,28
Ratio PEG	+0,24
Ratio P/B	−52,12
Ratio P/S	0,00

Perfil de la empresa

Achieve Life Sciences, Inc. ist ein pharmazeutisches Unternehmen im klinischen Stadium, das Cytisiniclin für die Raucherentwöhnung und Nikotinsucht in Kanada, den Vereinigten Staaten und Großbritannien entwickelt und vermarktet. Das Unternehmen bietet Cytisinicline an, ein pflanzliches Alkaloid, das mit Nikotinrezeptoren im Gehirn interagiert und so die Schwere der Nikotinentzugssymptome verringert. Es hat Lizenzvereinbarungen mit Sopharma AD und der Universität von Bristol. Das Unternehmen hat seinen Sitz in Vancouver, Kanada.

Nombre	Achieve Life Sciences
CEO	Andrew D. Goldberg
Sede	Bothell, wa Estados Unidos
Sitio web	achievelifesciences.com
Industria	Equipos y suministros sanitarios
Salida a bolsa	12/10/1995
Empleados	28